Abstract
You have accessJournal of UrologyBenign Prostatic Hyperplasia: Surgical Therapy & New Technology IV1 Apr 2017PD27-03 THE NEW MEDITATE® TEMPORARY IMPLANTABLE NITINOL DEVICE (I-TIND) IN THE TREATMENT OF BLADDER OUTLET OBSTRUCTION DUE TO BPH: RESULTS OF ONE ARM, MULTI-CENTER PROSPECTIVE, STUDY Francesco Porpiglia, Cristian Fiori, Daniele Amparore, Arya Manit, Gregor Kadner, Massimo Valerio, and Claude Shulman Francesco PorpigliaFrancesco Porpiglia More articles by this author , Cristian FioriCristian Fiori More articles by this author , Daniele AmparoreDaniele Amparore More articles by this author , Arya ManitArya Manit More articles by this author , Gregor KadnerGregor Kadner More articles by this author , Massimo ValerioMassimo Valerio More articles by this author , and Claude ShulmanClaude Shulman More articles by this author View All Author Informationhttps://doi.org/10.1016/j.juro.2017.02.1224AboutPDF ToolsAdd to favoritesDownload CitationsTrack CitationsPermissionsReprints ShareFacebookTwitterLinked InEmail INTRODUCTION AND OBJECTIVES Temporary Implantable Nitinol Device (TIND - MediTate®) is a new device for the treatment of lower urinary tract symptoms (LUTS) due to benign prostatic hyperplasia (BPH). We already published the feasibility and safety of TIND implantation, herein we report the results of a one-arm, multi-center, international prospective study to assess the efficacy of second generation of MediTate i-TIND in subjects with BPH. METHODS The i-TIND is comprised of three nitinol elongated struts and an anchoring leaflet and it is preloaded by crimping it into the delivery system. In expanded configuration, the struts of the i-TIND exert radial force that causes ischemic necrosis and subsequent incisions of bladder neck and prostatic urethra. i-TIND was implanted under light sedation, using a rigid 22F cystoscope. The device was removed 5 days later in an outpatient setting, with no need of anesthesia. Forty patients with LUTS were enrolled in this multi-center study from Oct 2014. Inclusion criteria were: IPSS score = 10, peak urinary flow (Qmax) < 12 ml/sec and prostate volume < 75 cc. All patients discontinued medical therapy for BPH before the implantation. Demographics, perioperative, functional results and quality of life (QoL) were evaluated. For the purpose of this study we reported the results of 3 and 6 months follow-up. RESULTS Patients’ age (mean+ SD) was 65.7 y (9.1) and BMI (mean+ SD) was 26.5 (4.1). Prostate volume (mean+ SD), IPSS score (median, range), QoL (median, range) and Qmax (mean+ SD), were 35.3 (+12.5) cc, 25(13-35), 4 (2-5), and 7.5 (2.87) ml/sec respectively. All the implantations and the removals of device were successfully concluded with no intraoperative complications. Three months after implantation IPSS score, QoL and Qmax were 7 (1-29), 1 (0-5) and 12.4ml/sec (4.9); after six months were 7 (0-29), 2 (0-4) and 14 ml/sec (+6.01) respectively. No patients reported ejaculatory dysfunction during follow-up. Differences in terms of IPSS score, QoL and Qmax when comparing preoperative and 6 months postoperative results were statistically significant (p<0.05); specifically the mean change from baseline to month 6 in IPSS score was -15.33 and the mean change of Qmax was 6.2 ml/sec. During the follow up no patients required pharmacologic treatment or surgery for BPH. CONCLUSIONS Second generation i-TIND implantation is a safe and effective minimally-invasive option for the treatment of BPH related LUTS at least at short term follow up. Further studies are required to assess durability of these results. © 2017FiguresReferencesRelatedDetails Volume 197Issue 4SApril 2017Page: e512 Advertisement Copyright & Permissions© 2017MetricsAuthor Information Francesco Porpiglia More articles by this author Cristian Fiori More articles by this author Daniele Amparore More articles by this author Arya Manit More articles by this author Gregor Kadner More articles by this author Massimo Valerio More articles by this author Claude Shulman More articles by this author Expand All Advertisement Advertisement PDF downloadLoading ...
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Disclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.